One study demonstrated improved hematologic recovery and median overall survival (OS) in MM patients receiving ≥5 × 106 CD34+ cells/kg [9], while a post-hoc analysis of the GOA trial demonstrated no discernable difference in progression-free survival (PFS) or OS across three CD34+ dose groups (<1.0 × 106 CD34+ cells/kg, 1–1.9 × 106 CD34+ cells/kg, and ≥2 × 106 CD34+ cells/kg) [10]. The gene discussed is CD34; the disease is Miyoshi myopathy.